Case-Based Roundtable Meetings Spotlight: July 1, 2022

During a Targeted Oncology case-based roundtable event, Cyrus M. Khan, MD, discussed the data supporting the use of polatuzumab, bendamustine, and rituximab, tasfasitamab plus lenalidomide, and loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, discussed therapeutic sequencing for patients with unresectable hepatocellular carcinoma and the use of lenvatinib versus sorafenib.

During a Targeted Oncology case-based roundtable event, Pedro Barata, MD, MSc, discussed the case of a patient with clear cell renal cell carcinoma who progressed following frontline treatment with axitinib/pembrolizumab.

During a case-based roundtable event, David A. Rizzieri, MD, discussed the case of a 68-year-old patient with myelofibrosis.

Michael R. Bishop, MD, discussed a patient with graft-versus-host disease who first underwent a myeloablative conditioning regimen and peripheral blood stem-cell matched hematopoietic cell transplant as treatment.

Experts discuss the newest approaches for treating patients with diffuse large B-cell lymphoma.

Tiffany A. Traina, MD, discussed the ASCENT Trial examining patients with triple negative breast cancer.

During a Targeted Oncology case-based roundtable event Thomas E. Stinchcombe, MD, discussed the case of a 53-year-old patient with extensive-stage small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Jan A. Burger, MD, PhD, discussed data supporting the use of ibrutinib, acalabrutinib, and zanubrutinib for first-line treatment of chronic lymphocytic leukemia.

During a Targeted Oncology case-based roundtable event, Rana R. McKay, MD, discussed updates to key trials in advanced clear cell renal cell carcinoma.

During a case-based roundtable event, Joshua K. Sabari, MD, discussed the case of a 73-year-old woman with extensive-stage small cell lung cancer.